Kornimate/medical-research-clean huggingface dataset:
adolescent dysmenorrhea endometriosis assessment magnetic resonance imaging (adodream)

Conditions: Endometriosis

Summary: to date, no mri study has been published describing the prevalence of endometriosis in adolescent girls, not even in those with significant dysmenorrhea and therefore more particularly at risk. likewise, there are no precise data on the type of superficial or early-onset deep endometriosis that appears in adolescence. the collection of these data would allow an earlier diagnosis, because it is better documented, of endometriosis. the lesions would then be treated earlier, avoiding their development and the problems of infertility related to this pathology. the aim of this sudy is to assess the prevalence of endometriosis and its phenotypic representation in the study population consulting for dysmenorrhea with suspected endometriosis.


Eligibility criteria:
inclusion criteria: * patient aged between 12 and 20 years old. * after menarche. * requiring pelvic mri for exploration of dysmenorrhea (after or not ultrasound), in the case of patients with suspected endometriosis, or for any other reason (cyst, tumor, non-obstructive urogenital malformations), in the case of patients without symptoms clinic associated with endometriosis. * patient affiliated or beneficiary of a social security scheme. * patient and her legal representative, if applicable, having been informed and not opposing this research. exclusion criteria: * patient whose pelvic mri is performed as part of an exploration of obstructive uterine malformations. * patient claustrophobic, making it impossible to perform an mri. * contraindication to mri: pacemaker, ferromagnetic object incompatible with mri. * pregnant, breastfeeding or parturient woman. * protected patient: major under guardianship, curatorship or other legal protection, deprived of liberty by judicial or administrative decision; hospitalized without consent.
safety and pharmacology study of snx-5422 in subjects with refractory hematological malignancies

Conditions: Cancer

Summary: hsp90 is a chemical in the body that is involved int he promotion of cancer. snx-5422 is an experimental drug that blocks hsp90.

snx-5422 is a prodrug for snx-2112. correlation has been observed between hsp90 client protein level changes and functional effects in cells in in vitro studies of snx-2112, supporting inhibition of hsp90 as the mechanism of action for this compound. snx-5422 has demonstrated significant antitumor activity in mouse xenograft models of human tumors, including breast (bt474, mx-1), colon (ht29), prostate (pc3), and melanoma (a375) with multiple oral dosing regimens. pharmacokinetic (pk) studies in mice, rats, and dogs have shown high bioavailability of snx-2112 following oral administration of snx 5422. in mouse xenograft studies, snx-2112 was selectively retained in tumor tissue compared with other tissues. this study will employ critical risk management features including the use of the nci common terminology criteria for adverse events (ctcae) version 4.03, which provides a scale for consistently grading the severity of aes, toxicity criteria analyses for dose escalation, frequent laboratory and clinical observations, correlation of aes with plasma concentrations of snx-5422 and snx-2112, monitoring of the qtc interval at appropriate time points, and a conservative dose-escalation scheme.

Eligibility criteria:
inclusion criteria: * males or non-pregnant, non-breastfeeding females 18 years-of-age or older with histologically confirmed non-hodgkins lymphoma, without known or clinically suspected cns involvement, that is refractory to available therapy or for which there is no available therapy. * no more than 4 prior lines of systemic anti-cancer therapy and no prior bone marrow transplant or stem cell transplant within 12 months of dosing, and no prior allogeneic transplant. * karnofsky performance score ≥60 * life expectancy of at least 3 months. * adequate baseline laboratory assessments exclusion criteria: * currently receiving anticancer therapy or have received anticancer therapy within the past 28 days or 5 half-lives of the anticancer therapy * the need for treatment with medications with clinically-relevant metabolism by the cytochrome p450 (cyp) 3a4 isoenzyme within 3 hours before or after administration of snx-5422 * at increased risk for developing prolonged qt interval, including hypokalemia or hypomagnesemia, unless corrected to within normal limits prior to first dose of snx-• chronic diarrhea. * gastrointestinal diseases or conditions that could affect drug absorption, including gastric bypass. * gastrointestinal diseases that could alter the assessment of safety, including irritable bowel syndrome, ulcerative colitis, crohn's disease, or hemorrhagic coloproctitis. * history of documented adrenal dysfunction not due to malignancy. * seropositive for human immunodeficiency virus (hiv) or hepatitis c virus (hcv). * history of chronic liver disease

Keywords: hematological malignancy hsp90
genetic factors and pheochromocytomas in neoplasia type 2

Conditions: Neoplasia; Pheochromocytoma

Summary: multiple endocrine neoplasia type 2a (men2a) is a rare syndrome associated with activating mutations in the ret proto-oncogene, combining medullary thyroid cancer in approximately 100% of cases and pheochromocytoma in 10-80% of cases. while it is accepted that the ret mutation causes variable penetrance of pheochromocytoma in the men2a patient population, there is no pathophysiological explanation for the phenotypic variability among patients with the same mutation, including within the same family. the aim of this study is to better characterise the genetic factors that may explain the variable penetrance of pheochromocytoma in men2. to this end, the investigatoes plan to perform a whole exome analysis in 2 families carrying the p. cys634arg mutation causing nem2a, followed in marseille by the principal investigator: the 1st family has 11 members all aged over 35 years, for which 8 are carriers of pheochromocytoma while 3 have not developed it (while their age is higher than the latest age of diagnosis of pheochromocytoma in this family); the 2nd family has 3 members (father and daughter with pheochromocytoma developed before 25 years; son without pheochromocytoma at an age of 42 years). the investigators believe that the analysis of these patients should allow the isolation of variants on genes potentially involved in the genesis of a pheochromocytoma in men2.


Eligibility criteria:
inclusion criteria: * patient aged 18 years or older * male or female patient * patient followed in the investigating department for familial nem2a c634r (multiple endocrine neoplasia type 2) with or without pheochromocytoma * patient affiliated to or benefiting from a social security scheme * patient having given his non-opposition to participate in this study * patient who has given his consent for the genetic analysis carried out in the framework of the study * patient able to understand the purpose of the study exclusion criteria: * protected persons (articles l1121-5, l1121-6 and l121-8 of the public health code): pregnant or breastfeeding women, persons deprived of their liberty, under guardianship or curator * patients unable to understand the purpose of the study and the information note

Keywords: neoplasia pheochromocytoma
study of clinic-based vs. self-use of a misoprostol-only regimen for induced abortion

Conditions: Induced Abortion; First Trimester Abortion

Summary: the goal of the study is to determine whether important clinical outcomes differ among women who access a misoprostol-only medication abortion regimen from a patent medicine vendor when compared with those who access it from a clinic.

medication abortion with a misoprostol-only regimen within the first 10 weeks of pregnancy is safe and effective. investigators aim to assess whether self-use of early (\<9 weeks) medication abortion using a misoprostol-only regimen results in non-inferior rates of clinical outcomes when compared with clinic-based provision of medication abortion. the investigators will prospectively recruit women who obtain misoprostol from patent medicine vendors and clinics. follow-up will occur by telephone during three phone calls within 45 days of the first dose of misoprostol.

Eligibility criteria:
inclusion criteria: * purchased a misoprostol-only abortion regimen at a pmv or from a clinic * be at least 15 years of age * have a known lmp of less than 9 weeks * no contraindications to medical abortion * willing and able to give informed consent * have a mobile phone of which they are the independent user or be willing to be followed-up in person * willing to be contacted with questions about her abortion by telephone at 1-3, 10-29 and 30-45 days following initial contact. exclusion criteria: * contraindications to misoprostol * age \ 49

Keywords: medication abortion misoprostol
attitude and perception towards covid-19 pandemic

Conditions: COVID-19

Summary: assess response and attitude of general population living in sharkia governerate, egypt as regard covid-19 pandemic through arabic questionnaire.


Eligibility criteria:
inclusion criteria: * general population within age range (16-70) and both sexes living in sharkia governerate, egypt and accept to participate exclusion criteria: * below 16 or above 70 years * refuse to participate * duplicate answers * incomplete answers
maternal hypotension during cesarean section and short term neonatal outcome.

Conditions: Elective Cesarean Section; Maternal Hypotention

Summary: about 20-25% of deliveries are by cesarean section. most are elective with use of regional anesthesia (spinal/epidural). drop of blood pressure after regional anesthesia is common. it have the risk of reduction of blood flow to the placenta and the fetus. no studies had followed the newborns their first days of live,of mothers who developed hypotension in durins cs.

a reterospective study of all full term babies, born in elective cesarean section with use of regional anesthesia. two groups will be define rgarding maternal hypotention following regional anesthesia - maternal hypotention (study group) or normal maternal bp. the definition of maternal hypotension: decrease in 10% or more in mean bp in compared to first bp taken at admition. data will colect from mothers and neonates records as well as operation data. maternal data: gravida, parity, diseases, medications, demographics, and all data regarding the operation (blood pressures, heart rates, saturation, treatment given etc.). infant data: gestational age, birth weight, sex, apgar, cord ph, clinical manifestations, medications, time of hospitalization.

Eligibility criteria:
inclusion criteria: * fullterm infants, born by elective cesarean section using regional anasthesia. exclusion criteria: * preterms, urgent cs, cs using general anasthesia, multiple pregnancy, congenital malformations.

Keywords: regional anestesia cesarean section hypotention newborn
surgical stress index as a tool for monitoring analgesia and/or sedation in critically ill patients

Conditions: Analgesia; Sedation; Mechanical Ventilation; Pain; Stress; Intensive Care Unit; Critical Care

Summary: the hypothesis of the study is: does the surgical stress index (ssi) correlate with the behavioral pain scale (bps), the ramsay sedation scale (rss)and/or the behavioral pain scale(bpv) and can therefore be used to monitor the quality of analgosedation in noncommunicative intensive care unit patients?

the surgical stress index (ssi) was developed as a bedside tool to measure 'pain' during surgery. first trials showed a good correlation between ssi and aching procedures and a negative correlation to the dosage of remifentanil. the first evaluation studies were performed under propofol and remifentanil anaesthesia. a different site of use for the surgical stress index could be the intensive care medicine. 'analgesia and sedation are essential elements of intensive care treatment and relevant for patient outcome... there is therefore a need to monitor and define the level of sedation and pain and to provide the critically ill patient with adequate analgesia and sedation.' (j. martin 2002). although the ramsey sedation scale was never proven for validity and reliability it is an often used score for measurement of sedation quality. (ramsay 74, hansen-flaschen 94, jacobi 02, martin 04). the behavioral pain scale showed , apart from systolic blood pressure and heart rate, to be reliable and valid for measuring pain in noncommunicative, mechanical ventilated intensive care unit patients. (payen 01, jacobi 02, aissaoui 05) these scales need to be performed a few times a day to be up to date and therefore time consuming for the intensive care staff. the surgical stress index could be a non-invasive, bedside and online tool for measurement of sedation and/or analgesia in this complex patient group.

Eligibility criteria:
inclusion criteria: * analgosedated, mechanically ventilated patients on the icu exclusion criteria: * neurological disorder * age under 18 * lack of sinus rhythm

Keywords: analgesia sedation critical illness intensive care
anticoagulation with rivaroxaban in cardioversion -the arc study

Conditions: Atrial Fibrillation; Stroke; Thrombo-embolism; Bleeding

Summary: the purpose of this study is to determine that a new drug called "rivaroxaban®" is effective in preventing patients from forming clots after their heart rhythm has been reset by the cardiologist with an electrical device.

patient who are electrically cardioverted require 1 month of anticoagulation (blood thinner). rivaroxaban a xa-inhibitor has been shown to be non-inferior to warfarin (vit k antagonist) the current standard of care in many treatment areas. rivaroxaban will be compared to warfarin historical control group studying the safety and efficacy in electrically cardioverted patients.

Eligibility criteria:
inclusion criteria: * patients with non-valvular atrial fibrillation requiring electrical cardioversion o atrial fibrillation of unknown duration exclusion criteria: * patients requiring extended anticoagulation after cardioversion due to concomitant risk factors as defined by chads2 score ≥ 1 * significant renal dysfunction (crcl \<15ml/min) * significant hepatic dysfunction (childs-pugh class b or c) * history of coagulopathy * active bleeding * hypersensitivity to rivaroxaban * concomitant use of anticoagulants * concomitant use of potent cyp3a4/p-gp inhibitors or inducers * interventions requiring interruption of therapy * pregnancy * age \<18 y/o * history of gi bleed

Keywords: rivaroxaban warfarin anticoagulation stroke thrombo-embolism bleeding atrial fibrillation cardioversion
ivabradine to prevent anthracycline-induced cardiotoxicity

Conditions: Patients With Cancer

Summary: the aim of this study is to investigate protective effects of ivabradine in adult cancer patients undergoing anthracycline-based chemotherapy.

cancer treatment with anthracyclines may cause heart damage and can lead to heart failure. there are drugs which may protect against cardiotoxic effects of anthracyclines (renin-angiotensin inhibitors and beta blockers), but they are not tolerated due to hypotension. ivabradine is heart rate lowering drug without effect on blood pressure which was approved for treatment of angina pectoris and heart failure. the aim of this study is to investigate protective effects of ivabradine in cancer patients undergoing anthracycline-based chemotherapy. ivabradine selectively inhibits if currents in the sinus node and prolongs the duration of spontaneous depolarization. that controls the heart's contractions and regulates the heart rate. additionally, ivabradine might preserve myocardial function and contractility without effect on blood pressure. ivabradine was approved for symptomatic treatment of chronic stable angina pectoris and chronic heart failure. the aim of this study is to investigate protective effects of ivabradine in adult cancer patients undergoing anthracycline-based chemotherapy.

Eligibility criteria:
inclusion criteria: * cancer patients undergoing anthracyclines based chemotherapy; * heart rate (hr) \> 70 times per minute; * written informed consent. exclusion criteria: * contraindications for ivabradine administration; * hr\<70 times per minute; * incapability to complete informed consent; * severe valve disease; * left ventricular ejection fraction (lvef)≤ 30 %; * other severe conditions; * poor echogenicity.

Keywords: anthracycline chemotherapy cardiotoxicity heart failure
mild therapeutic hypothermia during severe sepsis

Conditions: Sepsis

Summary: objectives: to evaluate the feasibility, the safety and the effects on physiological parameters of mild therapeutic hypothermia during septic shock. design: a randomized, controlled, pilot physiological study. setting: a 15-beds university-affiliated intensive care unit of a teaching hospital. patients: twenty ventilated and sedated adults patients with septic shock intervention: mild therapeutic hypothermia between 32 and 34°c during 36 consecutive hours using an external water cooling blanket.


Eligibility criteria:
inclusion criteria: * age \> 18-yrs, * sedation and mechanical ventilation for at least 48-hrs, * the diagnosis of septic shock according to standard guidelines. exclusion criteria: * bradycardia \< 50 bpm, or any severe ventricular rhythm disturbances, * pregnancy, * need for emergent surgery or any other complementary exam involving patient transport within the sixth hours following inclusion, * decision to withdraw or withhold life support, * predictable death within six hours.

Keywords: sepsis, septic shock, therapeutic hypothermia
safety, efficacy and pharmacokinetics of cf-301 vs. placebo in addition to antibacterial therapy for treatment of s. aureus bacteremia

Conditions: Staphylococcus Aureus Bacteremia; Staphylococcus Aureus Endocarditis

Summary: the purpose of this study is to evaluate the safety, tolerability, efficacy and pharmacokinetics (pk) of cf-301 in addition to background standard of care (soc) antibacterial therapy for the treatment of staphylococcus aureus (s. aureus) bloodstream infections (bacteremia), including endocarditis in adults. patients will be randomized to receive a single intravenous dose of cf-301 or placebo in addition to soc antibacterial therapy. patients will be prescribed standard of care antibiotics selected by the investigators based on their professional experience, practice guidelines and local antibiotic susceptibility information for the treatment of s. aureus bacteremia. cf-301 is a lysin and member of a new class of targeted protein-based antimicrobials that has demonstrated activity against s. aureus in laboratory (in vitro) and animal studies, alone and in addition to conventional antibiotics.


Eligibility criteria:
inclusion criteria: * male or female, 18 years or older * blood culture positive for s. aureus * at least one sign or symptom attributable to s. aureus bacteremia * known or suspected complicated s. aureus bsi and/or endocarditis by modified duke criteria * patient is not pregnant or breastfeeding and is not of reproductive potential or agrees to use contraception if of reproductive potential. exclusion criteria: * patient previously received cf-301. * treatment with any potentially effective (anti-staphylococcal) systemic antibiotic for more than 72 hours within 7 days before randomization. * presence of any removable infection source that will not be removed or debrided within 72 hours after randomization. * brain abscess or meningitis. * community acquired pneumonia or known polymicrobial bacteremia

Keywords: staphylococcus aureus bacteremia staphylococcal endocarditis
cognitive correlates of substance abuse - 11

Conditions: Amphetamine-Related Disorders

Summary: the purpose of this study is to characterize the cognitive performance of methamphetamine abusers by comparing them with cocaine abusers and normal controls.


Eligibility criteria:
inclusion criteria: m/f . meet dsm-iv criteria for cocaine or methamphetamine dependence. agree to conditions of the study and sign informed consent.

Keywords: amphetamine dependence
investigation of performance and compatibility of the baxter dialyzer xenium xph 210 during on-line hemodiafiltration

Conditions: End Stage Kidney Disease

Summary: the proposed study seeks to determine the appropriate balance between the removal of undesirable small molecular substances (urea, creatinine, phosphate) and large molecular substances (ß2-m) and the retention of important substances (e.g.albumin) for the baxter xenium xph dialyzer type under defined therapeutic conditions of olhdf primarily concerning filtration flow rates in relation to blood flow/plasma water flow rates. furthermore the possibility of the removal of certain protein-bound substances shall be investigated together with the impact of increasing ultrafiltration on the parameters of the micro-inflammation.

the new high flux dialyser membrane xenium xph 210 from baxter will show an considerably increased removal of ß2-microglobulin with olhdf in post dilution mode together with a markedly increased removal of small molecules (urea, creatinine, phosphate). the loss of albumin will depend on the treatment modalities. however, the albumin permeability is tolerable over the whole range of total filtration rate selected and applied to the patients. together with the albumin loss into the filtrate/dialysate a small amount of albuminbound substances is detectable. parameters of micro-inflammation can be influenced by an increasing convective part of the treatment.

Eligibility criteria:
inclusion criteria: * patients who have signed an informed consent form. * patients between 18 and 75 years. * patients who have been treated with hemodialysis for more than three months. * patients who are treated three times a week for 4-5 hours. * patients who are usually treated with high-flux dialyzers. * patients who are on a stable anticoagulation and erythropoetin regimen. * patients whose hematocrit is over 28 %. * patients having no vascular access related problems. exclusion criteria: * patients not meeting the inclusion criteria. * patients who are in a poor nutritional status as judged by the investigator. * patients in a gravid state. * patients with an unstable clinical condition (e.g. cardiac or vascular instability). * patients whose life expectancy is less than 12 months. * patients with a positive anamnesis for the first use syndrome. * patients with known coagulation problems. * patients who receive hemodialysis via a single dialysis needle or central venous catheter. * patients participating in another study that may interfere with the outcome of the present study.

Keywords: hemodialysis on line postdilution high-flux dialyzer hemodiafiltration